Welcome Jobo. Great to have a real expert here commenting.
Where I think CU6 has a real advantage is their bis-PMSA construct is able to target the tumour better allowing the longer half-life Cu67 to be more effective while minimising off-target side-effects. There have been no serious side-effects seen even using the 12MBq dose - this is 50% above the AC225 and Lu177 dose level that can be tolerated.
I really hope they push the Cu67 dose to MTD, but it looks like they aren't planning this. It is much easier to convince a clinician to switch to a treatment with superior efficacy than it is to convince them to switch to a new treatment with equal efficacy and less side effects.
CU6 - General discussion, page-292
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.57 |
Change
-0.240(3.52%) |
Mkt cap ! $2.103B | |||
| Open | High | Low | Value | Volume |
| $6.81 | $6.92 | $6.49 | $5.954M | 890.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 987 | $6.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.58 | 951 | 7 |
View Market Depth
| Last trade - 13.46pm 16/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |